Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fragmin in chronic neuroischaemic diabetic foot ulcers
NCT00662831Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2008
- Primary completion
- Oct 2010
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of dalteparin in diabetic foot ulcer (DFU), sponsored by Pfizer. Primary endpoint: Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing at 24 weeks. Started Apr 2008; status: completed.
02
Drugs
dalteparin
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT00662831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662831.